BioSpace News Archive

Mission Bio, announced new findings from the lab of Elías Campo, Director of the August Pi i Sunyer Biomedical Research Institute (IDIBAPS) in Barcelona, Spain, which used single-cell DNA sequencing to identify genetic drivers of Richter’s syndrome, the unpredictable and often deadly progression from chronic lymphocytic leukemia (CLL) to an aggressive B cell lymphoma.

A new study published in Frontiers in Neurology, one of the most-cited journals in its field, details important data on mode of action, pharmacodynamics, and toxicity data of Petasites for migraine prevention.

Pixium Vision SA announces that Lloyd Diamond, Chief Executive Officer of Pixium Vision, will attend virtually the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference, taking place on Wednesday 17 August, 2022.

According to Vision Research Reports, the cancer immunotherapy market size is expected to hit around US$ 130.6 billion by 2030 from valued at US$ 60.1 billion in 2020 and is anticipated to grow at a CAGR of 10.6% during forecast period 2021 to 2030.

The global cell banking outsourcing market was surpassed at USD 9.8 billion in 2021 and is expected to hit around USD 35.77 billion by 2030, growing at a CAGR of 15.38% from 2022 to 2030

According op Vision Research Reports, the global Anaesthesia information management systems market was surpassed at USD 464.7 billion in 2021 and is expected to hit around USD 774.82 billion by 2030, growing at a CAGR of 5.84% from 2022 to 2030

Cullgen Inc., a leading biotechnology company developing targeted protein degraders based on its proprietary uSMITE™ platform technology, announced that the Chinese National Medical Products Administration has allowed the Investigational New Drug application for CG001419, a TRK degrader for the treatment of solid tumors.

ThermoGenesis Holdings, Inc., a market leader in automated cell processing tools and services in the cell and gene therapy field, reported financial and operating results for the second quarter ended June 30, 2022 and provided a corporate strategic update.

Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for the quarter ended June 30, 2022 and provided a corporate update.

Regen BioPharma, Inc. announced the filing with the United States Patent and Trademark Office of a provisional US patent application covering the Company’s novel approach for enabling chimeric antigen receptor -T cell-based therapies to kill solid tumors through prevention of a process called “T cell exhaustion”.